| Literature DB >> 17304047 |
Emanuela Taioli1, Simone Benhamou, Christine Bouchardy, Ingolf Cascorbi, Nohelia Cajas-Salazar, Heike Dally, Kwun M Fong, Jill E Larsen, Loic Le Marchand, Stephanie J London, Angela Risch, Margaret R Spitz, Isabelle Stucker, Brian Weinshenker, Xifeng Wu, Ping Yang.
Abstract
Myeloperoxidase is a phase I metabolic enzyme that converts the metabolites of benzo[a]pyrene from tobacco smoke into highly reactive epoxides. A polymorphism in the promoter region of myeloperoxidase (463G-->A) has been found to be inversely associated with lung cancer; differences in the association with age and gender have been suggested. We conducted a pooled analysis of individual data from 10 studies (3688 cases and 3874 controls) from the Genetic Susceptibility to Environmental Carcinogens database. The odds ratio for lung cancer was 0.88 (95% confidence interval: 0.80-0.97) for the AG variant of myeloperoxidase G-463A polymorphism, and 0.71 (95% confidence interval: 0.57-0.88) for the AA variant after adjusting for smoking, age, gender, and ethnicity. The inverse association between lung cancer and myeloperoxidase G-463A polymorphism was equally found in males and females (odds ratio for the AA genotype 0.73 [95% confidence interval: 0.56-0.96] and 0.67 [95% confidence interval: 0.46-0.98], respectively), without differences in the association according to age in the two genders. The myeloperoxidase G-463A polymorphism was significantly protective in "ever" smokers but not in "never" smokers. Myeloperoxidase is a key enzyme in tobacco-induced carcinogenesis.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17304047 DOI: 10.1097/gim.0b013e31803068b1
Source DB: PubMed Journal: Genet Med ISSN: 1098-3600 Impact factor: 8.822